🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

659 results for “MS” Clear

  1. Ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Multiple Sclerosis (RMS)

    phase 3 mab active

    3 trials

  2. Ublituximab, ublituximab

    TG THERAPEUTICS, INC.

    Relapsing forms of Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  3. V114

    Merck KGaA, Darmstadt, Germany

    Acute Otitis Media (AOM)

    phase 3 mab completed

    1 trial

  4. V114

    Merck KGaA, Darmstadt, Germany

    Pneumococcal Infections

    phase 3 mab completed

    1 trial

  5. V181

    Merck KGaA, Darmstadt, Germany

    Healthy

    phase 3 mab active

    1 trial

  6. Vericiguat

    Merck KGaA, Darmstadt, Germany

    Chronic Heart Failure With Reduced Ejection Fraction

    phase 3 small molecule completed

    1 trial

  7. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, FLUOROURACIL, OPDIVO 10 mg/mL concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion, DISODIUM FOLINATE

    Bristol-Myers Squibb Australia Pty Ltd

    Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)

    phase 3 small molecule active

    1 trial

  8. Yorvipath 420 micrograms/1.4 mL solution for injection in pre‑filled pen, Yorvipath 168 micrograms/0.56 mL solution for injection in pre-filled pen, Yorvipath 294 micrograms/0.98 mL solution for injection in pre‑filled pen

    Ascendis Pharma Bone Diseases A/S

    Chronic hypoparathyroidism

    phase 3 small molecule active

    1 trial

  9. Zanidatamab

    BEONE MEDICINES AUS PTY LTD

    Gastric Neoplasms

    phase 3 small molecule active

    1 trial

  10. Zilovertamab vedotin

    Merck KGaA, Darmstadt, Germany

    Diffuse Large B-Cell Lymphoma

    phase 3 mab active

    1 trial

  11. aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

    Regeneron UK Limited

    Ovarian Neoplasms

    phase 3 small molecule completed

    2 trials

  12. albuterol (Armstrong Albuterol HFA)

    Amphastar France Pharmaceuticals

    Asthma

    phase 3 small molecule terminated

    1 trial

  13. albuterol HFA (Armstrong's)

    Amphastar France Pharmaceuticals

    Asthma

    phase 3 small molecule terminated

    1 trial

  14. cetuximab + cisplatin + vinorelbine

    Merck KGaA, Darmstadt, Germany

    Non Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule completed

    1 trial

  15. deucravacitinib, Placebo to match BMS 986165 tablet

    Bristol-Myers Squibb Australia Pty Ltd

    Moderate-to-Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  16. elritercept, Placebo to match ker-050 solution for injection

    Takeda

    myelodysplastic neoplasms/syndromes (MDS)

    phase 3 small molecule active

    1 trial

  17. favezelimab/pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Colorectal Cancer

    phase 3 mab completed

    1 trial

  18. folic acid

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colorectal Neoplasms

    phase 3 small molecule active

    1 trial

  19. lapatinib

    GlaxoSmithKline

    Neoplasms, Breast

    phase 3 small molecule completed

    1 trial

  20. pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Non-small Cell Lung Cancer

    phase 3 mab completed

    2 trials

  21. pembrolizumab/vibostolimab

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Non-Small-Cell Lung

    phase 3 mab active

    1 trial

  22. pemetrexed

    Eli Lilly and Company

    Head and Neck Neoplasms

    phase 3 small molecule completed

    1 trial

  23. preoperative short-course radiotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Neoplasms

    phase 3 other terminated

    1 trial

  24. ublituximab

    TG THERAPEUTICS, INC.

    relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources